US Bancorp DE Acquires 2,268 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

US Bancorp DE raised its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 22.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,430 shares of the biopharmaceutical company’s stock after buying an additional 2,268 shares during the quarter. US Bancorp DE’s holdings in Sage Therapeutics were worth $67,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in SAGE. Geode Capital Management LLC boosted its stake in Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock worth $8,975,000 after purchasing an additional 3,757 shares during the period. Quest Partners LLC boosted its position in shares of Sage Therapeutics by 56.3% during the third quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 6,618 shares during the period. SG Americas Securities LLC grew its holdings in shares of Sage Therapeutics by 57.7% during the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 8,228 shares in the last quarter. Ieq Capital LLC acquired a new stake in Sage Therapeutics in the 4th quarter valued at approximately $57,000. Finally, Dynamic Technology Lab Private Ltd raised its position in Sage Therapeutics by 100.9% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 28,549 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 14,340 shares during the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Stock Performance

Shares of SAGE opened at $8.02 on Tuesday. The firm has a market cap of $493.08 million, a P/E ratio of -1.22 and a beta of 0.82. Sage Therapeutics, Inc. has a 52 week low of $4.62 and a 52 week high of $20.32. The firm’s 50-day simple moving average is $7.18 and its 200 day simple moving average is $6.70.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. As a group, equities analysts forecast that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SAGE has been the subject of several research reports. TD Cowen decreased their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Thursday, November 21st. HC Wainwright reaffirmed a “neutral” rating and issued a $12.00 target price (down previously from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Royal Bank of Canada raised shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a research report on Thursday, November 21st. Bank of America initiated coverage on Sage Therapeutics in a report on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 price objective for the company. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, February 12th. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.81.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.